PATH has launched a groundbreaking initiative to address the rising burden of hemoglobinopathies—particularly Thalassemia—in ...

"Beta Thalassemia Market"In 2020, there are more than 900 beta-thalassemia major patients and more than 200 beta-thalassemia intermedia patients living in the UK. Emerging therapies for Beta ...

Around 5.2% of the global population carries abnormal hemoglobin genes. Each year, 300,000 to 500,000 children are born with severe hemoglobinopathies worldwide, with approximately 80% of these cases ...

The groundbreaking treatment can now also be used to treat transfusion-dependent beta thalassemia in people 12 and older. Like sickle cell, beta thalassemia is an inherited blood disorder. The FDA’s ...

CLEVELAND, Ohio -- Cleveland Clinic Children’s Hospital is among the first in the country to use a new gene therapy to treat patients with thalassemia, a genetic blood disorder that affects the ...

Britain's medicines regulator has authorized the world's first gene therapy treatment for sickle cell disease, in a move that could offer relief to thousands of people with the crippling disease in ...

Agios entered a distribution agreement with NewBridge in 2024, focusing on regulatory filings and commercialisation.